Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$4.02M-$4.02MN/M vs Q2 2024 EPS Diluted-$0.45-$0.45N/M vs Q2 2024 Operating Income-$3,827,800N/M Operating Cash Flowderived-$5,417,456N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,264,060N/M ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end